I thought it was interesting that they are being more open/explicit about the effectiveness -
"One such assay, based on split GFP complementation, has shown Phylomer FPPs to be 37-160 times more efficient at cytoplasmic delivery than conventional CPPs such as TAT or R9. "
I got the impression from the investor call that they are ready to define the next level of CPP as FPP and this may be the first phase in establishing PYC as the market leader (possibly only one?) in this space. Hayes said on the call they are 18 months - 2 years ahead of the competition if I recall correctly.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.025(1.95%) |
Mkt cap ! $731.9M | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.29 | $1.26 | $4.614M | 3.648M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19982 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.27 | 15462 | 4 |
View Market Depth
| Last trade - 13.30pm 26/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |